Key facts
- Persephone Biosciences’s last known valuation is $37.3M (Oct 2024).
- It has raised $21.6M across 3 recorded rounds; the latest was Seed Round ($317K) in Feb 2021.
- Notable investors include Y Combinator, Pioneer Fund, Gaingels, Springboard Enterprises, ZhenFund — 31 tracked in total.
- Persephone Biosciences has filed 1 Form D with the SEC, most recently Mar 2021 ($317K sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 31 names
- ·Watchlist + deal alerts for Persephone Biosciences
Funding rounds
3 roundsAbout Persephone Biosciences
Developer of equitable precision medicines designed to focus on microbial therapeutics for immuno-oncology applications. The company's medicines use artificial intelligence and omics techniques on multiple cancer patient gut microbiomes and blood samples to identify microbes needed for normal immune function for population-scale patient data analytics, enabling lab researchers to design microbial drugs that prevent and fight cancer.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2017
- Employees
- 22
- Website
- persephone.bio/
- Ownership
- Privately Held (backing)
Persephone Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Persephone Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Persephone Biosciences in its N-PORT filings yet. We sweep new filings monthly.